Sandy put the kibosh on thousands of business meetings this week. But could a missed meeting kill a company? Med-tech company Coaxia hopes it doesn't find out. The company is nearly out of cash and badly needs FDA approval of a product to combat ischemic stroke. But the FDA panel set to offer an opinion was canceled by the superstorm.
Shared publiclyView activity